Allergan defense vs. Valeant/Pershing Square

A company’s own rebuttal deck, built on advisor analysis, arguing a hostile bid line by line rather than in a courtroom.

Goldman Sachs · Bank of America Merrill Lynch · 2014 · $53B · 12 slides · DEFA14A exhibit

1
2
3
4
5
6
7
8
9
10
11
12

Slide 1 of 12
Slide 2 of 12
Slide 3 of 12
Slide 4 of 12
Slide 5 of 12
Slide 6 of 12
Slide 7 of 12
Slide 8 of 12
Slide 9 of 12
Slide 10 of 12
Slide 11 of 12
Slide 12 of 12